| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2016-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-106459177-B |
| titleOfInvention |
High affinity ny-eso T cell receptor |
| abstract |
A kind of T cell receptor (TCR) and its fusion molecule with therapeutic agent are provided, the TCR can be used alone at least twice that the binding affinity of SLLMWITQC HLA A2 compounds is wild type TCR, the TCR, can be also combined with therapeutic agent. |
| priorityDate |
2015-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |